Back to Search Start Over

PD-L1 Dysregulation in COVID-19 Patients.

Authors :
Sabbatino F
Conti V
Franci G
Sellitto C
Manzo V
Pagliano P
De Bellis E
Masullo A
Salzano FA
Caputo A
Peluso I
Zeppa P
Scognamiglio G
Greco G
Zannella C
Ciccarelli M
Cicala C
Vecchione C
Filippelli A
Pepe S
Source :
Frontiers in immunology [Front Immunol] 2021 Jun 07; Vol. 12, pp. 695242. Date of Electronic Publication: 2021 Jun 07 (Print Publication: 2021).
Publication Year :
2021

Abstract

The COVID-19 pandemic has reached direct and indirect medical and social consequences with a subset of patients who rapidly worsen and die from severe-critical manifestations. As a result, there is still an urgent need to identify prognostic biomarkers and effective therapeutic approaches. Severe-critical manifestations of COVID-19 are caused by a dysregulated immune response. Immune checkpoint molecules such as Programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) play an important role in regulating the host immune response and several lines of evidence underly the role of PD-1 modulation in COVID-19. Here, by analyzing blood sample collection from both hospitalized COVID-19 patients and healthy donors, as well as levels of PD-L1 RNA expression in a variety of model systems of SARS-CoV-2, including in vitro tissue cultures, ex-vivo infections of primary epithelial cells and biological samples obtained from tissue biopsies and blood sample collection of COVID-19 and healthy individuals, we demonstrate that serum levels of PD-L1 have a prognostic role in COVID-19 patients and that PD-L1 dysregulation is associated to COVID-19 pathogenesis. Specifically, PD-L1 upregulation is induced by SARS-CoV-2 in infected epithelial cells and is dysregulated in several types of immune cells of COVID-19 patients including monocytes, neutrophils, gamma delta T cells and CD4+ T cells. These results have clinical significance since highlighted the potential role of PD-1/PD-L1 axis in COVID-19, suggest a prognostic role of PD-L1 and provide a further rationale to implement novel clinical studies in COVID-19 patients with PD-1/PD-L1 inhibitors.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Sabbatino, Conti, Franci, Sellitto, Manzo, Pagliano, De Bellis, Masullo, Salzano, Caputo, Peluso, Zeppa, Scognamiglio, Greco, Zannella, Ciccarelli, Cicala, Vecchione, Filippelli and Pepe.)

Details

Language :
English
ISSN :
1664-3224
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
34163490
Full Text :
https://doi.org/10.3389/fimmu.2021.695242